3 news items
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
SAVA
8 May 24
are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
SAVA
25 Mar 24
discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money
- Prev
- 1
- Next